Search results for "CROHN DISEASE"

showing 10 items of 196 documents

Ultrasonography and Transmural Healing in Crohn’s Disease

2015

MaleCrohn's diseasemedicine.medical_specialtyHepatologybusiness.industryGastroenterologyMEDLINEmedicine.diseaseSeverity of Illness IndexCrohn DiseaseInternal medicineIntestine SmallSeverity of illnessHumansImmunologic FactorsMedicineFemaleDrug MonitoringUltrasonographybusinessUltrasonographyClinical Gastroenterology and Hepatology
researchProduct

HIF-Overexpression and Pro-Inflammatory Priming in Human Mesenchymal Stromal Cells Improves the Healing Properties of Extracellular Vesicles in Exper…

2021

Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) have therapeutic potential in the treatment of several immune disorders, including ulcerative colitis, owing to their regenerative and immunosuppressive properties. We recently showed that MSCs engineered to overexpress hypoxia-inducible factor 1-alpha and telomerase (MSC-T-HIF) and conditioned with pro-inflammatory stimuli release EVs (EVMSC-T-HIFC) with potent immunomodulatory activity. We tested the efficacy of EVMSC-T-HIFC to repolarize M1 macrophages (Mφ1) to M2-like macrophages (Mφ2-like) by analyzing surface markers and cytokines and performing functional assays in co-culture, including efferocytosis and T-cel…

MaleCrohn’s diseasemedicine.medical_treatmentimmunomodulationMiceIntestinal mucosaCrohn DiseaseMedicineBiology (General)TelomeraseSpectroscopyCell PolarityGeneral MedicineComputer Science ApplicationsChemistryCytokinemacrophage repolarizationhypoxia-inducible factor 1-alphaCytokinesmesenchymal stromal cellsMyofibroblastGastroenterología y hepatologíaQH301-705.5CatalysisArticleInorganic ChemistryExtracellular VesiclesYoung AdultImmune systemCell AdhesionHuman Umbilical Vein Endothelial CellsAnimalsHumansPhysical and Theoretical ChemistryColitisEfferocytosisQD1-999Molecular BiologyAcute colitisbusiness.industryOrganic ChemistryMesenchymal stem cellMesenchymal Stem Cellsmedicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitDisease Models AnimalTrinitrobenzenesulfonic AcidCancer researchbusiness
researchProduct

Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammator…

2019

BACKGROUND Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined. METHODS In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis. RESULTS A total of 631 patients (late-onset 153, adult-onset 161, young adult-onset 317) were included. Colonic disease was more frequent in late-onset (P < 0005), stenosing behaviour was more frequent than in adult-onset (P < 0003), but fistulising disease was uncommon. Surgery rates were not different between the three age groups. Syste…

MaleDiseaseConstriction PathologictumoursInflammatory bowel diseaseLate Onset DisordersCohort Studiessurgery0302 clinical medicineCrohn DiseaseLate Onset DisordersMedicineYoung adultDigestive System Surgical ProceduresCrohn's diseaseGastroenterologyIleitisMiddle AgedColitisItaly030220 oncology & carcinogenesisoutcome030211 gastroenterology & hepatologyFemaleColorectal NeoplasmsCohort studysteroidsAdultmedicine.medical_specialtyAdolescentcomorbiditieselderly03 medical and health sciencesYoung AdultInternal medicineIntestinal FistulaHumansImmunologic FactorsGlucocorticoidsAgedRetrospective StudiesPolypharmacyHepatologybusiness.industrythiopurinesRetrospective cohort studymedicine.diseasecomorbidities; elderly; outcome; steroids; surgery; thiopurines; tumoursPolypharmacyTumor Necrosis Factor Inhibitorsbusiness
researchProduct

Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients With Inflammatory Bowel Disease

2019

Background Inflammatory bowel disease ( IBD ) is characterized by a low prevalence of traditional risk factors, an increased aortic pulse‐wave velocity ( aPWV ), and an excess of cardiovascular events. We have previously hypothesized that the cardiovascular risk excess reported in these patients could be explained by chronic inflammation. Here, we tested the hypothesis that chronic inflammation is responsible for the increased aPWV previously reported in IBD patients and that anti‐TNFa (anti‐tumor necrosis factor‐alpha) therapy reduce aPWV in these patients. Methods and Results This was a multicenter longitudinal study. We enrolled 334 patients: 82 patients with ulcerative colitis, 85 pati…

MaleLongitudinal studyTime FactorsSettore MED/09 - Medicina InternaAorta ThoracicBlood Pressure030204 cardiovascular system & hematologyGastroenterologyInflammatory bowel diseaseulcerative coliti0302 clinical medicineRisk Factorsarterial stiffneVascular DiseaseTumor necrosis factor-alphaEndoscopy Digestive SystemProspective Studies030212 general & internal medicinePulse wave velocityOriginal ResearchCrohn diseasetumor necrosis factor‐alphaUlcerative colitisC-Reactive Proteinarterial stiffnessCardiovascular DiseasesHypertensionFemaleTumor necrosis factor alphamedicine.symptomCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtypulse wave velocityInflammationPulse Wave Analysis03 medical and health sciencesVascular StiffnessInternal medicinemedicineHumansIn patientulcerative colitisbusiness.industryInflammatory Bowel Diseasesmedicine.diseasearterial stiffness; Crohn disease; inflammation; pulse wave velocity; tumor necrosis factor‐alpha; ulcerative colitis; Cardiology and Cardiovascular MedicineinflammationArterial stiffnessbusinessBiomarkersFollow-Up Studies
researchProduct

Diffuse malignant biphasic peritoneal mesothelioma with cystic areas

2016

We report a case of peritoneal biphasic mesothelioma with cystic areas in a patient with professional exposure to asbestos. It showed focal epithelial glandular and papillary proliferations, also presenting fluid filled cysts, whose wall consisted of a proliferation of spindle cells. Atypia and mitoses were very scanty. EMA, vimentin, CK5/6, D2-40, calretinin and P53 were positive and desmin was negative in both epithelial and spindle areas, including the ones surrounding the cystic spaces. These findings gave an essential aid in the differential diagnosis with a benign cystic mesothelioma and with a cystic epithelial mesothelioma with secondary pseudosarcomatous myofibroblastic proliferati…

MaleMesotheliomaLung NeoplasmsMesothelioma MalignantAscitesAsbestosMesothelioma CysticPemetrexedSettore MED/08 - Anatomia PatologicaAppendicitisCystic Mesothelioma Immunohistochemistry Malignant Mesothelioma Peritoneal Diseases Mesothelial Neoplasms.Diagnosis DifferentialSettore MED/18 - Chirurgia GeneraleCrohn DiseaseOccupational ExposureAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorHumansCisplatinDiagnostic ErrorsPeritoneal NeoplasmsAged
researchProduct

Unusual B cell morphology in inflammatory bowel disease.

2012

B lymphocytes express various different types of surface immunoglobulins that are largely unrelated to other hematological lines, although some reports have described a relationship between malignant B cells and other cells such as macrophages. Multiple genes of hematopoietic lineage, including transcription factors, are co-expressed in hematopoietic stem cells and progenitors, a phenomenon referred to as "lineage priming". Changes in the expression levels and timing of transcription factors can induce the lineage conversion of committed cells, which indicates that the regulation of transcription factors might be particularly critical for maintaining hierarchical hematopoietic development. …

MalePathologyCD79BiopsyUlcerativeSmallInflammatory bowel diseaseInflammatory bowel diseaseMucosal immunityCrohn DiseaseIntestine SmallLymphocytesMicroscopyB-Lymphocytesmedicine.diagnostic_testMiddle AgedColitisFucosyltransferasesIntestineSurfaceHaematopoiesismedicine.anatomical_structureAntigens SurfaceFemaleStem cellB-1 B cellsAdultmedicine.medical_specialtyLymphocyte homingColonLewis X AntigenBiologyFluorescencePathology and Forensic MedicineAntigeninflammatory bowel diseaseBiopsymedicineHumansCell LineageProgenitor cellAntigensB cellInflammatory bowel disease; Inflammation; Mucosal immunity; Lymphocytes; B-1 B cells; Lymphocyte homing; CD15+cells; Adult; Antigens Surface; B-Lymphocytes; Biomarkers; Biopsy; Cell Lineage; Cell Nucleus; Colitis Ulcerative; Colon; Crohn Disease; Female; Fucosyltransferases; Humans; Immunoglobulin M; Inflammatory Bowel Diseases; Intestine Small; Lewis X Antigen; Male; Microscopy Fluorescence; Middle Aged; RectumInflammationCell NucleusRectumCell Biologymedicine.diseaseInflammatory Bowel DiseasesImmunoglobulin MMicroscopy FluorescenceImmunologyColitis UlcerativeCD15+cellsBiomarkersPathology, research and practice
researchProduct

Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease

2015

Crohn's disease-related inflammation is characterized by reduced activity of the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels of SMAD7, an inhibitor of TGF-β1 signaling. Preclinical studies and a phase 1 study have shown that an oral SMAD7 antisense oligonucleotide, mongersen, targets ileal and colonic SMAD7.In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of mongersen for the treatment of persons with active Crohn's disease. Patients were randomly assigned to receive 10, 40, or 160 mg of mongersen or placebo per day for 2 weeks. The primary outcomes were clinical remission at day 15, defined as a Crohn's Disease Activit…

MaleSMAD7 antisense oligonucleotidemedicine.medical_treatmentOligonucleotidesPharmacologyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologylaw.inventionACTIVATIONImmunosuppressive AgentGlucocorticoidRandomized controlled trialCrohn DiseaselawOligonucleotideMedicineYoung adultCrohn's diseaseSettore MED/12 - GastroenterologiabiologyINDUCTIONMedicine (all)Remission InductionGeneral MedicineMiddle AgedCrohn's diseaseCytokineC-Reactive ProteinCombinationDrug Therapy CombinationFemaleDrugImmunosuppressive AgentsCOLITISHumanAdultmedicine.medical_specialtyAdolescentINFLAMMATORY-BOWEL-DISEASE PLACEBO-CONTROLLED TRIAL NECROSIS-FACTOR-ALPHA TGF-BETA-1-MEDIATED SUPPRESSION COLITIS INDUCTION ACTIVATION EFFICACY THERAPY MICEPlaceboSmad7 ProteinDose-Response RelationshipYoung AdultPharmacotherapyDouble-Blind MethodDrug TherapyInternal medicineHumansAntisenseGlucocorticoidsAgedDose-Response Relationship Drugbusiness.industryC-reactive proteinNECROSIS-FACTOR-ALPHAOligonucleotides AntisenseTGF-BETA-1-MEDIATED SUPPRESSIONEFFICACYmedicine.diseaseClinical trialMICEbiology.proteinbusinessAdolescent; Adult; Aged; C-Reactive Protein; Crohn Disease; Dose-Response Relationship Drug; Double-Blind Method; Drug Therapy Combination; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Oligonucleotides; Oligonucleotides Antisense; Remission Induction; Smad7 Protein; Young Adult; Medicine (all)INFLAMMATORY-BOWEL-DISEASE
researchProduct

Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.

2020

This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions

MaleTime FactorsDiseaseInflammatory bowel diseaseInflammatory bowel diseasesurgeryAnti-TNFBiological Factors0302 clinical medicineAnti-TNF Immunosuppressants Inflammatory bowel disease SurgeryCrohn DiseaseimmunosuppressantsRisk Factorsanti‐TNFGastroenterologyAge FactorsMiddle AgedUlcerative colitisNatural history030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleImmunosuppressive AgentsCohort studyAdultmedicine.medical_specialtyMedicinaDisease-Free Survival03 medical and health sciencesEarly surgeryYoung AdultGastrointestinal Agentsinflammatory bowel diseaseInternal medicinemedicineHumansSurvival analysisRetrospective StudiesHepatologybusiness.industryTumor Necrosis Factor-alphamedicine.diseasedigestive system diseasesInfliximabImmunosuppressantsSurgeryColitis Ulcerativebusiness
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score An…

2020

INTRODUCTION: Patients with Crohn's disease experiencing endoscopic postoperative recurrence (POR) may benefit from antitumor necrosis factor (TNF) agents but scarce data on this are available. Our aim was to assess the efficacy of anti-TNF in improving mucosal lesions in patients with endoscopic POR. METHODS: Multicenter, retrospective, study of patients with Crohn's disease who underwent therapy with anti-TNF agents for endoscopic POR (Rutgeerts score > i1). Treatment outcomes were assessed by the findings in the last ileocolonoscopy performed after anti-TNF therapy was initiated. Endoscopic improvement and remission were defined as any reduction in the baseline Rutgeerts score and by a R…

Maleintestinal resectionrecurrent diseaseretrospective studyAnti-Inflammatory AgentsLogistic regressionGastroenterologyimmunology0302 clinical medicineCrohn DiseasepreventioncolonoscopyRecurrenceInterquartile rangeadalimumabIntestinal MucosariskCrohn's diseaseazathioprineMercaptopurinedrug effectGastroenterologyclinical trialColonoscopyTNF protein humanfemaleTreatment Outcomemesalazine030220 oncology & carcinogenesisintestine mucosaFemaleDrug Therapy Combination030211 gastroenterology & hepatologydouble-blindantiinflammatory agentImmunosuppressive Agentsmanagementmedicine.drugcombination drug therapyAdultmedicine.medical_specialtyAdolescentdiagnostic imagingtumor necrosis factormercaptopurineArticleYoung Adult03 medical and health sciencesInternal medicinemedicineAdalimumabHumanshumanproceduresPropensity ScoreRetrospective StudiestherapyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseAdalimumabassociationnatural-historyOdds ratioimmunosuppressive agentmedicine.diseaseInfliximabInfliximabConfidence intervalmulticenter studyConcomitantpathologybusiness
researchProduct